Initially unresectable colon cancer
Showing 26 - 50 of >10,000
Colon Cancer, Rectal Cancer Trial in New York (Floxuridine, Oxaliplatin, CPT-11)
Completed
- Colon Cancer
- Rectal Cancer
- Floxuridine, Oxaliplatin, CPT-11
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jun 29, 2021
PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only
Not yet recruiting
- PARP Inhibitor for Esophageal Squamous Cell Carcinoma
- Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
- (no location specified)
Sep 24, 2023
Colorectal Cancer, Colon Cancer, Rectal Cancer Trial in Newport Beach (hMN14 (labetuzumab))
Completed
- Colorectal Cancer
- +6 more
- hMN14 (labetuzumab)
-
Newport Beach, CaliforniaHoag Cancer Center
Aug 12, 2021
Liver Metastasis Colon Cancer Trial in Petach Tikva (oxaliplatin, FOLFIRI Protocol, Bevacizumab)
Recruiting
- Liver Metastasis Colon Cancer
- oxaliplatin
- +2 more
-
Petach Tikva, IsraelRabin Medical Center
Oct 16, 2020
Multimodal Deep Learning Radiomic Nomogram for Evaluation of
Not yet recruiting
- Colorectal Cancer
- Liver Metastases
-
Shanghai, Shanghai, ChinaZhongshan hospital
Jan 4, 2023
Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)
Not yet recruiting
- Metastatic Colorectal Cancer
- Cetuximab + Envafolimab + mFOLFOXIRI
- Cetuximab + mFOLFOX6/FOLFIRI
- (no location specified)
Jul 24, 2023
Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemo, Unresectable Metastatic Right-sided
Recruiting
- Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy
- Unresectable Metastatic Right-sided Colon Cancer, Stage IV
- A-FOLFOXIRI
- Arm II (A-FOLFOX/A-FOLFIRI)
-
Seoul, Korea, Republic ofYonsei Cancer Center, Severance Hospital, Yonsei University Heal
Oct 15, 2020
Chemo, Radiation Therapy Trial in Fuzhou (Camrelizumab, Paclitaxel, Cisplatin)
Not yet recruiting
- Chemotherapy
- Radiation Therapy
- Camrelizumab
- +3 more
-
Fuzhou, ChinaFujian Medical University Union Hospital
Apr 6, 2023
Adult Solid Tumor, Bladder Carcinoma, Colon Carcinoma Trial in Duarte (Laboratory Biomarker Analysis, Modified Vaccinia Virus
Active, not recruiting
- Adult Solid Neoplasm
- +16 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor
Active, not recruiting
- Locally Advanced Bone Sarcoma
- +20 more
- Ipilimumab
- +3 more
-
Anchorage, Alaska
- +650 more
Oct 18, 2022
Liver Metastasis Colon Cancer Trial in Guangzhou (TACE and HAIC Combined With Regorafenib)
Not yet recruiting
- Liver Metastasis Colon Cancer
- TACE and HAIC Combined With Regorafenib
-
Guangzhou, Guangdong, Chinathe first affiliated hospital, Sun-Yat sen university
Oct 2, 2023
Colon Cancer, Colorectal Cancer, Rectal Cancer Trial in Worldwide (Panitumumab, Bevacizumab, mFOLFOX6)
Colon Cancer Trial (Neoadjuvant chemo)
Not yet recruiting
- Colon Cancer
- Neoadjuvant chemotherapy
- (no location specified)
Oct 25, 2023
Unresectable Gallbladder Cancer Trial in Guangzhou (Carrilizumab plus GEMOX)
Not yet recruiting
- Unresectable Gallbladder Cancer
- Carrilizumab plus GEMOX
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jun 16, 2023
NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)
Not yet recruiting
- Non-small Cell Lung Cancer Stage III
- radiotherapy
- +3 more
- (no location specified)
Sep 10, 2023
Liver Transplant Disorder, Hepatic Cancer Trial (assisted liver transplantation combined with two-stage hepatectomy)
Not yet recruiting
- Liver Transplant Disorder
- Hepatic Cancer
- assisted liver transplantation combined with two-stage hepatectomy
- (no location specified)
Mar 6, 2023
Mesothelioma, Bladder Cancer, Melanoma Trial in Australia, Canada, United States (MGD009)
Terminated
- Mesothelioma
- +12 more
- MGD009
-
Los Angeles, California
- +19 more
Feb 4, 2022
Locally Advanced, NSCLC Trial in Shanghai (drug, procedure, radiation)
Recruiting
- Locally Advanced
- Non-small Cell Lung Cancer
- Serplulimab
- +5 more
-
Shanghai, ChinaShanghai Pulmonary Hospital
Mar 14, 2023
Colon Cancer Liver Metastasis Trial in Brussels (NKR-2 cells)
Unknown status
- Colon Cancer Liver Metastasis
- NKR-2 cells
-
Brussels, BelgiumInstitut Jules Bordet
Jun 18, 2020
Colorectal Cancer, Metastatic Cancer Trial in United States (dexamethasone, floxuridine, fluorouracil)
Active, not recruiting
- Colorectal Cancer
- Metastatic Cancer
- dexamethasone
- +5 more
-
Basking Ridge, New Jersey
- +4 more
Feb 4, 2022
Metastatic Colorectal Cancer, Liver Metastases Trial in Guangzhou (Irinotecan, Oxaliplatin HAI, Floxuridine)
Not yet recruiting
- Metastatic Colorectal Cancer
- Liver Metastases
- Irinotecan
- +5 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 27, 2019
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Biospecimen Collection
- +9 more
-
Birmingham, Alabama
- +848 more
Aug 24, 2022
DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer Trial in Guangzhou (drug, radiation,
Recruiting
- DMMR Colorectal Cancer
- +2 more
- PD-1 Antibody
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 22, 2021
Colonic Tumors Trial in Moscow (Japanese pathological investigation, European pathological investigation)
Not yet recruiting
- Colonic Neoplasms
- Japanese pathological investigation
- European pathological investigation
-
Moscow, Russian FederationClinic of coloproctology and minimally invasive surgery
Nov 1, 2023
Colo-rectal Cancer, Liver Metastases Trial in Guangzhou (Irinotecan, Oxaliplatin, Floxuridine)
Unknown status
- Colo-rectal Cancer
- Liver Metastases
- Irinotecan
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 27, 2019